When the clinicopathological features were compared according to SMAD4 and RUNX3 expression status (Table 2), we found SMAD4 loss was associated with increased tumor size (p = 0.030), higher pN stage (AJCC 8th ed). This evidence concerns the gene RUNX3 and neoplasm.